New Insights on Treatment Strategies for mCRC:

Introduction

ESMO Guidelines: Cytoreduction as a Decision Driver

First-Line Treatment has a "Crucial Mission"

Consistent OS Benefit of Attaining ETS in More Recent Phase 3 Studies With Targeted Agents

ETS Correlates With Post-Progression Survival

Characteristics to Tailor Up-Front Treatment

Evidenced-Based First-Line Options Today

First-Line Treatment of mCRC: Cytoreduction in Fit Patients

FOLFOXIRI + Cetuximab: MACBETH Efficacy Results

FOLFOXIRI + Panitumumab: VOLFI Trial -- ORR (Primary Endpoint)

TRIPLETE Study: Phase 3 Trial

FIRE 4.5 (AIO KRK-0116) Study: Phase 2 Trial

ESMO Primary Tumor Location Pooled Analysis

Meta-Analysis: Response Rate

FOLFOXIRI + Anti-EGFR mAb

ESMO Primary Tumor Location Pooled Analysis

Mutations in RAS Emerge During Anti-EGFR Treatment and Decline When Treatment Is Suspended

Rechallenge With Anti-EGFR Drugs

Ongoing Clinical Trials Evaluating Anti-EGFR Rechallenge in mCRC

Possible Uses of "Liquid Biopsy"

Predictive Role of ctDNA: The CRICKET Study

NGS for ctDNA Analysis From Liquid Biopsy?

Comprehensive ctDNA Genomic Analysis by NGS (Guardant360) After Anti-EGFR Treatment in mCRC (N = 193)

High Intrapatient Genomic Heterogeneity and Subclonality Limit Treatment: Sym004-05 Clinical Trial

What Is the Clinical Relevance of Low Frequency Mutations What Is the Clinical Relevance of Low Frequency Mutations? TTD -- Platform Study

Treating Tumor Heterogeneity and Clonal Evolution

From Single Targeting to Multi-Targeting: Increasing Clinical Benefit in BRAF+ mCRC

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)